Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Giuseppe MinnitiDimitri AnzelliniChiara ReverberiGian Carlo Antonini CappelliniLuca MarchettiFederico BianciardiAlessandro BozzaoMattia OstiPier Carlo GentileVincenzo EspositoPublished in: Journal for immunotherapy of cancer (2019)
Concurrent SRS and ipilimumab or nivolumab show meaningful intracranial activity in patients with either asymptomatic and symptomatic melanoma brain metastases, although a subset of patients may develop symptomatic RN. The combination of nivolumab with SRS is associated with better intracranial control.